Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.

British journal of haematology - 1 Dec 2020

Chen Jiaqi, Wang Fang, Fang Jiancheng, Nie Daijing, Zhang Yang, Chen Xue, Li Yu, Tan Yincheng, Ma Xiaoli, Guo Yongxin, Cao Panxiang, Liu Ming, Liu Hongxing

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Imidazoles

Share to Leukemia

Share to Mutation

Share to Pyridazines

Source

Identifiers

PMID: 33460055
DOI: 10.1111/bjh.17068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.PMID 33460055Read ↗

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.Semantic proximity Read ↗

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.Semantic proximity Read ↗

Haematological cancer: Ponatinib in CML - keeping PACE with multiple mutations.Semantic proximity Read ↗

T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.Semantic proximity Read ↗

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.Semantic proximity Read ↗

BCR-ABL1 mutation ≠ ponatinib resistance.Semantic proximity Read ↗

BCR-ABL1 compound mutations drive ponatinib resistance.Semantic proximity Read ↗

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.Semantic proximity Read ↗

New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Resistance mutations in CML and how we approach them.Semantic proximity Read ↗

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based studySemantic proximity Read ↗

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.